Completed PHASE3 NCT00386308

Efficacy and Safety Study of XP12B in Women With Menorrhagia

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia

Sponsor: Ferring Pharmaceuticals

Conditions Heavy Menstrual Bleeding Menorrhagia

Interventions Placebo tablets Tranexamic acid tablets

Updated 7 times since 2017 Last updated: May 3, 2011 Started: Oct 31, 2006 Primary completion: May 31, 2008 Completion: May 31, 2008

A PHASE3 clinical study on Heavy Menstrual Bleeding and Menorrhagia, this trial is completed. The trial is conducted by Ferring Pharmaceuticals and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ferring Pharmaceuticals

Data source: Ferring Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Amite, United States , Atlanta, United States , Baton Rouge, United States , Canfield, United States , Carmichael, United States , Centerville, United States , Charleston, United States , Chattanooga, United States , Cleveland, United States and 38 more locations